Table 3.
Compound | Activity IC50 [µM] a | ||
MCF-7 | |||
24 h | 48 h | 72 h | |
DOX | 3.42 ± 0.03 | 0.58 ± 0.02 | 0.57 ± 0.02 |
DOX-micelles | 1.96 ± 0.01 | 0.52 ± 0.02 | 0.13 ± 0.01 |
8HQ | 7.17 ± 0.21 | 2.86 ± 0.09 | 3.01 ± 0.05 |
8HQ-mic b | 4.82 ± 0.17 | 2.11 ± 0.11 | 0.75 ± 0.04 |
8HQ-Glu | 65.86 ± 2.22 | 62.07 ± 1.84 | 63.57 ± 2.01 |
8HQ-Glu-mic c | 37.57 ± 0.92 | 3.85 ± 0.19 | 0.59 ± 0.02 |
8HQ-Gal | 26.39 ± 1.28 | 23.15 ± 0.99 | 24.60 ± 0.52 |
8HQ-Gal-mic d | 5.59 ± 0.14 | 0.21 ± 0.01 | 0.19 ± 0.01 |
Compound | Activity IC50 [µM] a | ||
HCT-116 | |||
24 h | 48 h | 72 h | |
DOX | 6.94 ± 0.33 | 0.095 ± 0.01 | 0.105 ± 0.01 |
DOX-micelles | 2.36 ± 0.08 | 0.45 ± 0.01 | 0.078 ± 0.01 |
8HQ | 9.33 ± 0.22 | 4.12 ± 0.12 | 4.40 ± 0.08 |
8HQ-mic b | 4.95 ± 0.16 | 1.80 ± 0.05 | 0.91 ± 0.04 |
8HQ-Glu | 49.67 ± 1.32 | 47.20 ± 1.14 | 45.73 ± 1.81 |
8HQ-Glu-mic c | 49.60 ± 2.11 | 8.46 ± 0.12 | 0.38 ± 0.02 |
8HQ-Gal | 22.10 ± 0.84 | 23.09 ± 0.92 | 22.52 ± 1.02 |
8HQ-Gal-mic d | 10.83 ± 0.33 | 2.64 ± 0.12 | 0.017 ± 0.01 |
Compound | Activity IC50 [µM] a | ||
NHDF-Neo | |||
24 h | 48 h | 72 h | |
DOX | >20 | >20 | 2.71 ± 0.08 |
DOX-micelles | >20 | 3.93 ± 0.12 | 2.50 ± 0.06 |
8HQ | 9.34 ± 0.25 | 8.97 ± 0.19 | 9.64 ± 0.32 |
8HQ-mic b | 5.18 ± 0.26 | 3.96 ± 0.12 | 3.97 ± 0.09 |
8HQ-Glu | 41.00 ± 2.01 | 41.11 ± 1.73 | 30.02 ± 0.94 |
8HQ-Glu-mic c | 41.70 ± 1.42 | 22.53 ± 0.65 | 13.38 ± 0.39 |
8HQ-Gal | 20.14 ± 0.75 | 21.77 ± 0.89 | 18.30 ± 0.74 |
8HQ-Gal-mic d | 7.47 ± 0.17 | 5.55 ± 0.17 | 2.79 ± 0.13 |
a Cytotoxicity was evaluated using the MTT assay; b 8HQ-loaded micelles; c 8HQ-Glu-loaded micelles; d 8HQ-Gal-loaded micelles. Data are presented as the mean ± SD (n = 3).